1,528 Shares in Illumina, Inc. (NASDAQ:ILMN) Purchased by D.B. Root & Company LLC

D.B. Root & Company LLC bought a new stake in shares of Illumina, Inc. (NASDAQ:ILMN) in the 4th quarter, Holdings Channel.com reports. The fund bought 1,528 shares of the life sciences company’s stock, valued at approximately $204,000.

Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Empowered Funds LLC increased its stake in Illumina by 1.7% during the 3rd quarter. Empowered Funds LLC now owns 3,960 shares of the life sciences company’s stock worth $516,000 after buying an additional 66 shares during the period. Caprock Group LLC grew its stake in shares of Illumina by 3.0% during the third quarter. Caprock Group LLC now owns 2,884 shares of the life sciences company’s stock valued at $376,000 after acquiring an additional 83 shares in the last quarter. Integrated Advisors Network LLC increased its position in shares of Illumina by 2.0% during the third quarter. Integrated Advisors Network LLC now owns 4,484 shares of the life sciences company’s stock worth $585,000 after acquiring an additional 90 shares during the last quarter. Moors & Cabot Inc. lifted its stake in shares of Illumina by 1.7% in the third quarter. Moors & Cabot Inc. now owns 5,818 shares of the life sciences company’s stock worth $759,000 after acquiring an additional 95 shares in the last quarter. Finally, Carson Advisory Inc. boosted its holdings in Illumina by 3.8% in the third quarter. Carson Advisory Inc. now owns 2,757 shares of the life sciences company’s stock valued at $360,000 after purchasing an additional 102 shares during the last quarter. Institutional investors and hedge funds own 89.42% of the company’s stock.

Illumina Price Performance

Shares of NASDAQ ILMN opened at $134.76 on Friday. Illumina, Inc. has a 1-year low of $100.08 and a 1-year high of $156.66. The firm has a market capitalization of $21.37 billion, a PE ratio of -13.53 and a beta of 1.11. The company has a debt-to-equity ratio of 0.94, a current ratio of 2.43 and a quick ratio of 1.85. The business’s fifty day moving average price is $139.06 and its two-hundred day moving average price is $134.26.

Illumina (NASDAQ:ILMN) last issued its quarterly earnings data on Monday, November 4th. The life sciences company reported $1.14 earnings per share for the quarter, beating the consensus estimate of $0.88 by $0.26. The firm had revenue of $1.08 billion for the quarter, compared to the consensus estimate of $1.08 billion. Illumina had a negative net margin of 36.10% and a positive return on equity of 7.29%. Illumina’s quarterly revenue was down 3.5% compared to the same quarter last year. During the same period last year, the firm posted $0.33 EPS. On average, research analysts expect that Illumina, Inc. will post 4.13 EPS for the current year.

Wall Street Analyst Weigh In

ILMN has been the topic of several analyst reports. Citigroup downgraded Illumina from a “buy” rating to a “neutral” rating and dropped their price objective for the stock from $190.00 to $165.00 in a report on Wednesday, December 11th. Morgan Stanley cut their price target on shares of Illumina from $156.00 to $150.00 and set an “equal weight” rating on the stock in a report on Monday, January 13th. Piper Sandler decreased their price objective on shares of Illumina from $195.00 to $185.00 and set an “overweight” rating for the company in a report on Monday, November 11th. Robert W. Baird upped their target price on shares of Illumina from $124.00 to $139.00 and gave the company a “neutral” rating in a research note on Wednesday, November 6th. Finally, Barclays increased their price target on shares of Illumina from $135.00 to $145.00 and gave the stock an “equal weight” rating in a research report on Tuesday, November 5th. Eight analysts have rated the stock with a hold rating, eleven have issued a buy rating and two have given a strong buy rating to the stock. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average price target of $165.63.

Illumina Company Profile

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.